Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryRituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma.Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trialManagement of relapsed-refractory diffuse large B cell lymphoma.Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma.Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients.Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MA retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report.
P2860
Q27304386-9B55FFCD-4D8D-4D47-BB2D-F72C458323BEQ28088365-86894E18-44AA-4D90-996D-EB8682FD69A5Q33400583-75E84613-75D1-43C7-9748-20215AD7D42AQ33440659-67C290B2-9045-4ECD-A44E-AD75D994BB9EQ35986409-77D966E3-4F6A-4DEC-96B1-3C0B77A265B5Q37046984-E08CD974-570A-485F-94C6-C20BE957E9D0Q37273186-4C0B1C3B-BDD7-457D-B7B6-17DA243DBF28Q37654010-252D4BA6-E4C7-472C-AE76-0CC9E1F85043Q38260183-36D4A953-9FF7-429B-BE1D-10C585E53E59Q40578587-86FB406A-236A-4320-BC20-250725E4F768Q47752514-CD14D270-882E-4FBD-82CF-D28FFAA19F38Q48277333-43CAE9D2-A96E-48D9-8387-ED7949238289Q48371948-F1850223-8420-484F-8AEE-D6B9F2C958CEQ53153689-A97616F7-5FA9-4ED5-B8A9-4E2362EF66EEQ53214513-4A5D0F2F-5405-48BE-937B-122002AEB007Q55514591-7B8271BE-C3B8-416A-9ED1-1C83F336DF6F
P2860
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@ast
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@en
type
label
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@ast
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@en
prefLabel
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@ast
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
P356
P1476
Rituximab, dexamethasone, cyta ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
Catherine Thieblemont
Christian Gisselbrecht
David Sibon
Isabelle Madelaine
Josette Briere
Julie Lignon
Patricia Franchi
Pauline Brice
Pierre Faure
P304
P356
10.3816/CLML.2010.N.055
P407
P577
2010-08-01T00:00:00Z